Large-Vessel Vasculitis

Kathleen Maksimowicz-McKinnon; Gary S. Hoffman

doi:10.1055/s-2004-836148

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2004; 25(5): 569-579
DOI: 10.1055/s-2004-836148

Large-Vessel Vasculitis

Kathleen Maksimowicz-McKinnon¹ , Gary S. Hoffman²

¹Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania
²Department of Rheumatology and Immunology, Center for Vasculitis Care and Research, The Cleveland Clinic Foundation, Cleveland, Ohio

Abstract

The vasculitides affecting large and medium-sized vessels are heterogeneous. This group includes such disorders as giant cell arteritis, Takayasu's disease, and sarcoidosis. There are several challenges that may arise in the care of patients with these disorders.

Diagnosis may be elusive when initially evaluating patients with large-vessel vasculitis. Most serologic markers are not specific, and tissue biopsy is often impractical. We will present data emphasizing the most common disease manifestations, to aid in recognition of a clinical picture suggestive of large-vessel vasculitis. We will also focus on the more common pulmonary manifestations and minimize case reports, which may not reflect the usual course of disease.

Large cohort studies and randomized controlled trials to provide an evidence-based approach to therapy in these disorders are uncommon. We have included in this review discussion of those studies that we judged to be most rigorously conducted and clinically relevant. We provide guidelines for initial therapy, with caveats to assist in minimizing potential treatment-related complications and toxicities.

Although monitoring of disease activity is often difficult, this is a most crucial element in minimizing disease and treatment-associated morbidity and mortality.

KEYWORDS

Vasculitis - sarcoidosis - Takayasu's arteritis - giant cell arteritis

Volltext

Referenzen

REFERENCES

1 Nasu T. Takayasu's truncoarteritis in Japan: a statistical observation of 76 autopsy cases. Pathol Microbiol (Basel). 1975; 43 140-146
2 Hall S, Barr M D, Lie J T, Stanson A W, Kazmier F J, Hunder G G. Takayasu's arteritis: a study of 32 North American patients. Medicine. 1985; 64 89-99
3 Hata A, Noda M, Moriwaki R, Numano F. Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol. 1996; 54(suppl) S155-S163
4 Lupi-Herrera E, Sanchez-Torrez G, Marcushamer J et al.. Takayasu arteritis: clinical study of 107 cases. Am Heart J. 1977; 93 94-103
5 Subramanyan R, Joy J, Balakrishnan K G. Natural history of aortoaortitis (Takayasu's disease). Circulation. 1989; 80 429-437
6 Zhonggao W, Shen L, Yu J et al.. Management of cerebral ischemia due to Takayasu's arteritis. Chin Med J (Engl). 2002; 115 342-346
7 Moore P, Cupps T. Neurologic complications of vasculitis. Ann Neurol. 1983; 14 155-167
8 Kiyosawa M, Baba T. Ophthalmological findings in patients with Takayasu disease. Int J Cardiol. 1998; 66(suppl 1) S141-S147
9 Sheikhzadeh A, Tettenborn I, Noohi F, Eftekharzadeh M, Schnabel A. Occlusive thromboaortopathy (Takayasu disease): clinical and angiographic features and a brief review of literature. Angiology. 2002; 53 29-40
9a Sharma S, Kamalakar T, Rajani M, Talwar K K, Shrivastava S. The incidence and patterns of pulmonary artery involvement in Takayasu's arteritis. Clin Radiol. 1990; 42 177-181
9b Yamada I, Nakagawa T, Himeno Y et al.. Takayasu arteritis: diagnosis with breath-hold contrast-enhanced three-dimensional MR angiography. J Magn Reson Imaging. 2000; 11 481-487
9c Vanoli M, Castellani M, Bacchiani G et al.. Noninvasive assessment of pulmonary artery involvement in Takayasu's arteritis. Clin Exp Rheumatol. 1999; 17 215-218
9d Ogawa Y, Hayashi K, Sakamoto I, Matsunaga N. Pulmonary arterial lesions in Takayasu arteritis: relationship of inflammatory activity to scintigraphic findings and sequential changes. Ann Nucl Med. 1996; 10 219-223
10 Numano F, Kobayashi Y. Takayasu arteritis-beyond pulselessness. Intern Med. 1999; 38 226-232
11 Lie J T. Isolated pulmonary Takayasu arteritis: clinicopathological characteristics. Mod Pathol. 9 469-474
12 Haque U, Hellman D, Traill T, Venbrux A, Stone J. Takayasu's arteritis involving proximal pulmonary arteries and mimicking thromboembolic disease. J Rheumatol. 1999; 26 450-453
13 Kerr G, Hallahan C, Giordano J et al.. Takayasu arteritis. Ann Intern Med. 1994; 120 919-929
14 Castellote E, Romero R, Bonet J et al.. Takayasu's arteritis as a cause of renovascular hypertension in a non-Asian population. J Hum Hypertens. 1995; 9 841-845
14a Rose A G, Sinclair C C. Takayasu's arteritis: a study of 16 autopsy cases. Arch Pathol Lab Med. 1980; 104 231-237
14b Lagneau P, Michel J. Renovascular hypertension and Takayasu's disease. J Urol. 1985; 134 876-879
14c Chugh K S et al.. Nonspecific aortoarteritis is a major cause of renovascular hypertension in Asian countries. Proc Asian Pacific Cong Nephrol Beijing; 1990: 450-456
14d Sharma S, Rajani M, Kamalakar T, Talwar K K, Sunderam K R. Clinical and angiographic features of nonspecific aorto-arteritis in children and adults. Acta Radiol. 1991; 32 485-487
15 Tso E, Flamm S, White F et al.. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum. 2002; 46 1634-1642
16 Belhocine T, Blockmans D, Hustinx R, Vandevivere F, Mortelmans L. Imaging of large-vessel vasculitis with 18FDG PET: illusion or reality? A critical review of the literature data. Eur J Nucl Med Mol Imaging. 2003; 30 1305-1313
17 Hoffman G S. Takayasu arteritis: lessons from the American National Institutes of Health experience. Int J Cardiol. 1996; 54(suppl) S83-S86
18 Hoffman G S, Leavitt R Y, Kerr G S et al.. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum. 1994; 37 578-582
19 Shelhamer J H, Volkman D J, Parrillo J E et al.. Takayasu's arteritis and its therapy. Ann Intern Med. 1985; 103 121-126
20 Hoffman G S, Merkel P A, Brassington R D, Lenshcow D, Kissin E Y et al.. Utility of anti-TNF therapy in Takayasu's arteritis [abstract 1101]. Arthritis Rheum. 2003; 48(suppl)-S442
21 Deyu Z, Lisheng L, Ruping D, Haiying W, Guozhang L. Percutaneous transluminal renal angioplasty in aortoarteritis. Int J Cardiol. 1998; 66(suppl) S205-S211
22 Liang P, Tan-Ong M, Hoffman G S. Takayasu's arteritis: vascular interventions and outcomes. J Rheumatol. 2004; 31 102-106
23 Miyata T, Sato O, Koyama H, Shigematsu H, Tada Y. Long-term survival after surgical treatment of patients with Takayasu's arteritis. Circulation. 2003; 108 1474-1480
24 Lagneau P, Michel J B, Vuong P N. Surgical treatment of Takayasu's disease. Ann Surg. 1987; 205 157-166
25 Hoffman G S. Treatment of giant-cell arteritis: where we have been and why we must move on. Cleve Clin J Med. 2002; 69(suppl 2) SII117-SII120
25a Gonzalez-Gay M A, Bianco R, Rodrigues-Valverde V et al.. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998; 41 1497-1504
25b Chevalet P, Barrier J H, Pottier P et al.. A randomized, multicenter, controlled trial using intraversus pulses of methylprednisolone predissolving in the initial treatment of simple forms of giant cell arteritis: a one year follow-up study of 164 patients. J Rheumatol. 2000; 27 1484-1491
26 Brack A, Geisler A, Martinez-Taboada V M et al.. Giant cell vasculitis is a T cell-dependent disease. Mol Med. 1997; 3 530-543
27 Hunder G, Valente R. Giant cell arteritis: clinical aspects. In: Hoffman GS, Weyand CM Inflammatory Diseases of Blood Vessels New York, NY; Marcel Dekker 2002: 425-442
28 Mohan N, Kerr G. Spectrum of giant cell vasculitis. Curr Rheumatol Rep. 2000; 2 390-395
29 Aiello P D, Trautmann J C, McPhee T J et al.. Visual prognosis in giant cell arteritis. Ophthalmology. 1993; 100 550-555
30 Liozon E, Herrmann F, Ly K et al.. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med. 2001; 111 211-217
31 Hunder G G. Giant cell arteritis and polymyalgia rheumatica. In: Ruddy S, Harris ED Jr, Sledge CB Kelley's textbook of Rheumatology Philadelphia, PA; Saunders 2001: 1158
32 Hunder G G, Allen G L. Giant cell arteritis: a review. Bull Rheum. 1978-9; 29 980-986
33 Ostberg G. Morphological changes in the large arteries in polymyalgia rheumatica. Acta Med Scand. 1972; (suppl 33) 135-164
34 Ladanyi M, Fraser R S. Pulmonary involvement in giant cell arteritis. Arch Pathol Lab Med. 1987; 111 1178-1180
35 Wagenaar S SC, Westermann C JJ, Corrin B. Giant cell arteritis limited to large elastic pulmonary arteries. Thorax. 1981; 36 876-877
36 Larson T S, Hall S, Hepper N GG, Hunder G G. Respiratory tract symptoms as a clue to giant cell arteritis. Ann Intern Med. 1984; 101 594-597
37 Lie J T. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum. 1990; 33 1074-1087
38 Salvarani C, Silingardi M, Ghirarduzzi A et al.. Is duplex ultrasonography useful for the diagnosis of giant cell arteritis?. Ann Intern Med. 2002; 137 E232-E238
38a Proven A, Gabriel S E, Orces C, O'Fallon W M, Hunder G G. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003; 49 703-708
38b Hachulla E, Boivin V, Pastuerel-Michon U et al.. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol. 2001; 19 171-176
38c Liozon E, Roblot P, Paire D et al.. Anticardiolipin antibody levels predict flares and relapses in patients with giant cell (temporal) arteritis: a longitudinal study of 58 biopsy-proven cases. Rheumatology (Oxford). 2000; 39 1089-1094
38d Andersson R, Malmvall B E, Bengtsson B A. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand. 1986; 220 465-469
38e Jover J A, Hernanadez-Garcia C, Morado I C et al.. Combined treatment of giant-cell arteritis with methotrexate and prednisone. Ann Intern Med. 2001; 134 106-114
38f Hoffman G S, Cid M C, Hellmann D B et al.. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002; 46 1309-1318
39 Schumacher H R. Sarcoidosis. In: Koopman Arthritis and Allied Conditions Baltimore, MD; Williams & Wilkins 1997: 1689-1695
40 Neville E, Walker A N, James D G. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med. 1983; 52 525-533
41 Skold C M, Larsen F F, Rasmussen E, Pehrsson S K, Eklund A G. Determination of cardiac involvement in sarcoidosis by magnetic resonance imaging and Doppler echocardiography. J Intern Med. 2002; 252 465-471
42 Silverman K J, Hutchins G M, Bulkley B H. Cardiac sarcoidosis: a clinicopathological study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978; 58 1204-1215
43 Rendt K E, Hoffman G S. Systemic vasculitis in sarcoidosis. In Hoffman GS, Weyard CM Inflammatory Diseases of Blood Vessels New York, NY; Marcel Dekker 2001: 695-705
44 Takemura T, Shishiba T, Akiyama O et al.. Vascular involvement in cutaneous sarcoidosis. Pathol Int. 1997; 47 84-89
45 Crystal R G. Sarcoidosis. In: Fauci, Braunwald, Issel'bacher, et al Harrison's Principles of Internal Medicine New York, NY; McGraw-Hill 1998: 1925
46 Travis W D. Pathology of pulmonary granulomatous vasculitis. Sarcoidosis Vasc Diffuse Lung Dis. 1996; 13 14-27
47 Studdy P, Bird R, James D G. Serum angiotensin-converting enzyme (SACE) in sarcoidosis and other granulomatous disorders. Lancet. 1978; 2 1331-1334
48 Yamagishi H, Shirai N, Takagi M et al.. Identification of cardiac sarcoidosis with 13N-NH3/18F-FDG PET. J Nucl Med. 2003; 44 1030-1036
49 Utz J P, Limper A H, Kalra S et al.. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003; 124 177-185
50 Fernandes S, Singsen B, Hoffman G S. Sarcoidosis and systemic vasculitis. Semin Arthritis Rheum. 2000; 30 33-46

Kathleen Maksimowicz-McKinnonD.O.

University of Pittsburgh, Division of Rheumatology

3500 Terrace St., BST S718

Pittsburgh, PA 15261

eMail: kmaxdo@hotmail.com